Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11473 posts found.

FDA places partial clinical hold on BioCryst’s lead candidate, BCX9930

May 9, 2022 Sales and Marketing

The FDA has imposed a partial clinical hold on BioCryst’s Factor D inhibitor, BCX9930. The clinical hold arrives around a …
News

Case of monkeypox confirmed in England

May 9, 2022 Sales and Marketing

The UK Health Security Agency has confirmed that a person in England has been diagnosed with the monkeypox virus.The patient …
News

New data for Shionogi’s COVID-19 antiviral show rapid virus clearance

April 25, 2022 Sales and Marketing

Shionogi has announced new results from two late-breaking presentations of S-217622. This is an investigational 3CL protease inhibitor that was …
News

National shortage of HRT medication due to high demand

April 25, 2022 Sales and Marketing

The national shortage of HRT products could have an impact on some women, who may not be able to sleep …
News

EMA recommend new treatment option for severe postpartum haemorrhage

April 25, 2022 Sales and Marketing

Novo Nordisk has announced that the EMA Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …
News

Ukraine: crisis for people with chronic diseases

April 25, 2022 Sales and Marketing

Preliminary results from an ongoing nationwide health needs assessment, conducted by WHO in partnership with Premise, indicate that one in …
News

Recipharm announces closing of acquisitions of two major CDMOs

April 11, 2022 Sales and Marketing

Recipharm has announced the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics. The acquisitions …
News

Innovative therapy ‘tricks’ and destroys cancer cells

April 11, 2022 Sales and Marketing

A novel therapy studied at the Medical College of Wisconsin (MCW) Cancer Centre is headed for clinical trial in patients …
News

World leaders pledge $4.8 billion in 2022 Break COVID Now Summit

April 11, 2022 Sales and Marketing

World leaders in Germany, Ghana, Indonesia, and Senegal came together in the 2022 Break COVID Now Summit, co-hosted by vaccine …
News

‘Killer’ immunotherapy shows early promise

April 11, 2022 Sales and Marketing

A first of its kind immunotherapy which uses the immune system’s ‘natural killer cells’ could offer potential against a range …
News
leipzig_skyline

FlyPharma Conference Europe: New dates and location announced

April 4, 2022 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

FlyPharma Conferences are pleased to announce that FlyPharma Europe is returning as a live, in-person event in 2022.
News

AI test could predict effective cancer drug combinations in less than two days

April 4, 2022 Sales and Marketing

Scientists have created a prototype test that can predict which drug combinations are likely to work for cancer patients in …
News

FDA accepts Dupixent for Priority Review in patients 12+ with eosinophilic esophagitis

April 4, 2022 Sales and Marketing

The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab), in patients aged 12 …
News

New centre targets ‘undruggable’ cancers

April 4, 2022 Sales and Marketing

The new Centre for Protein Degradation has been launched, made possible by a £9 million donation to The Institute of …
News

COVID-19 vaccines now available for five to 11-year olds in England

April 4, 2022 Sales and Marketing

Parents and carers of five to 11-year olds in England can now book a low-dose COVID-19 vaccine for their children. …
News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024